Navigation Links
Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
Date:3/14/2012

>ABOUT REG1, REG2 and REG3 
Regado's lead program, the anticoagulant system REG1, consists of two agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin) with the second being its complementary active control agent (anivamersen).  Anivamersen can be used to selectively reverse (completely or partially) the anticoagulant effect of pegnivacogin.  REG1, recently completing phase 2b (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 has completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing shortly and will be indicated for antiplatelet therapy such as in treating diabetic vasculopathies.

ABOUT APTAMERS
Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucl
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
2. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
3. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
4. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
5. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
6. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
7. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
8. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014  IGI Laboratories, Inc. (NYSE MKT: ... of its offering of $125 million aggregate principal amount ... The Notes were offered and sold only to qualified ... Act of 1933, as amended (the "Securities Act"). ... of 3.75% per year, payable semiannually in arrears on ...
(Date:12/17/2014)... PCCA received the Autism Hope Alliance,s ... program seal for best practices in meeting needs ... practices, materials and goods that meet strict criteria ... affected by autism often have unique physical or ... found in food and medicine – for instance ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Electrocardiogram (ECG) Devices - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... million by 2016. The North America ... market share while Europe claims ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... biotechnology,company Crucell N.V., the Aeras Global TB Vaccine ... present a progress update,and immunology data from a ... "Tuberculosis Vaccines for the World" conference (Atlanta,Georgia, April ... Worcester, South,Africa and launched in May 2007, is ...
... Officer, to present interim results of the ... Injury, HOPKINTON, Mass., April 9, 2008 Alseres,Pharmaceuticals, ... 15, 2008, Dr.,Mark Hurtt, Chief Medical Officer, will discuss ... panel on Spinal Cord Injury Research,during a congressional briefing ...
Cached Medicine Technology:Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 2Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 3Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 4Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 5Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa 6Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 2Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 3Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... private insurance could boost the ranks of the uninsured , , ... going without health insurance for a period of time is ... survey has found. , These gaps in coverage, however, are ... insurance through public programs, such as Medicaid. , "The bad ...
... (Nasdaq: NUVA ), a medical device company ... for the spine, announced today that it has agreed ... focused on clinical approval of the PCM(R) cervical disc ... strategic acquisition allows NuVasive the potential to accelerate its ...
... ResMed Inc. (NYSE: RMD ), announced today ... results for the third quarter and nine months of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook.The conference ...
... mean a 10% decline in information recall, scientists say, ... teens go on a binge drinking episode, they may ... in their brain, a new MRI-based study suggests. , ... cells, the researchers said. This means that damage caused ...
... -- Revenues of $73.8 million, -- Gross ... of $12.8 million or $0.27 per diluted share, , ... "Lotus" or the,"Company") today reported its strong 2008 results with ... total net revenues; gross profit,increasing to $33.4 million, up 44% ...
... Ethicon Endo-Surgery today announced the ... are featured in 15 studies being presented at ... Surgeons (SAGES) Annual Meeting. Setting the stage for ... preliminary experiences with the devices during, or with ...
Cached Medicine News:Health News:More Americans Experiencing Gaps in Health Coverage 2Health News:More Americans Experiencing Gaps in Health Coverage 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 2Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 3Health News:NuVasive Announces Acquisition of Cervical Total Disc Replacement Device 4Health News:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2009 Results 2Health News:Binge Drinking May Damage Teens' Brains 2Health News:Binge Drinking May Damage Teens' Brains 3Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 2Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 3Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 4Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 5Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 6Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 7Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 8Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 9Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 10Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 11Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 12Health News:Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results 13Health News:Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages 2Health News:Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages 3Health News:Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured in 15 Presentations at Sages 4
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
... Arthrotek® Precision Hand Instruments were developed ... tactile feel, while still having an instrument ... spaces without the fear of the bending ... designed and manufactured to conform to the ...
Medicine Products: